ORCHESTRA BIOMED HOLDINGS INC. - ORDINARY SHARES

Orchestra BioMed Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update

27 Mar 2024 16:17:23 By Nasdaq GlobeNewswire

Orchestra BioMed Announces Appointment of Medical Device Industry Expert David Pacitti to Board of Directors

26 Mar 2024 08:00:00 By Nasdaq GlobeNewswire

Orchestra BioMed Demonstrates Strength of Cardiovascular Pipeline with Virtue® SAB and AVIM Therapy Presentations at CRT 2024 Annual Meeting

13 Mar 2024 08:00:00 By Nasdaq GlobeNewswire

Orchestra BioMed to Participate in Upcoming Investor Conferences

07 Mar 2024 08:00:00 By Nasdaq GlobeNewswire

Orchestra BioMed Announces Presentation of Results from Clinical Study Demonstrating Favorable Hemodynamic Effects of AVIM Therapy In Hypertensive Pacemaker Patients

06 Mar 2024 08:37:17 By Nasdaq GlobeNewswire

Orchestra BioMed Presents New Data Showing Sustained Clinically Meaningful Reduction in 24-Hour Ambulatory Systolic Blood Pressure in Hypertensive Pacemaker Patients Treated with AVIM Therapy for Over 3 Years

26 Feb 2024 08:00:00 By Nasdaq GlobeNewswire

Orchestra BioMed Announces Initiation of BACKBEAT Pivotal Study of AVIM Therapy in Hypertensive Pacemaker Patients

08 Jan 2024 07:30:00 By Nasdaq GlobeNewswire

Orchestra BioMed Reports Third Quarter 2023 Financial Results and Provides Business Update

13 Nov 2023 16:21:38 By Nasdaq GlobeNewswire

Orchestra BioMed to Present at Upcoming Investor Conferences

09 Nov 2023 16:42:43 By Nasdaq GlobeNewswire

Orchestra BioMed Granted FDA Approval of IDE to Initiate BACKBEAT Pivotal Study of BackBeat CNT™ for the Treatment of Hypertension in Pacemaker Patients

19 Sep 2023 07:30:00 By Nasdaq GlobeNewswire

Orchestra BioMed Reports Second Quarter 2023 Financial Results and Provides Business Update

10 Aug 2023 16:34:21 By Nasdaq GlobeNewswire

Orchestra BioMed™ Granted FDA Approval of IDE for U.S. Pivotal Study of Virtue® Sirolimus AngioInfusion Balloon™ in Patients with Coronary In-Stent Restenosis

08 Aug 2023 08:30:00 By Nasdaq GlobeNewswire

Orchestra BioMed Set to Join Russell 3000® and other FTSE Russell Indexes

26 Jun 2023 08:00:01 By Nasdaq GlobeNewswire

Orchestra BioMed Appoints Bill Little as Executive Vice President of Corporate Development and Strategy and Andrew Taylor as Chief Financial Officer

07 Jun 2023 08:30:00 By Nasdaq GlobeNewswire

Orchestra BioMed to Present at the Jefferies Global Healthcare Conference

01 Jun 2023 08:00:01 By Nasdaq GlobeNewswire

Orchestra BioMed Reports First Quarter 2023 Financial Results and Provides Business Update

12 May 2023 09:15:18 By Nasdaq GlobeNewswire

Orchestra BioMed to Present at Upcoming Investor Conferences

07 Mar 2023 08:00:01 By Nasdaq GlobeNewswire

Orchestra BioMed Announces Upcoming Presentations on BackBeat CNT™ and Virtue® SAB at CRT 2023

24 Feb 2023 08:00:00 By Nasdaq GlobeNewswire